DYAX –

Cambridge, Mass.

Went public 8/15/2000 at $15 per share

Filing Range: 4 mil. shares @ $13 to $15

Shares Outstanding: 18.1 mil. shares

Underwriters: J.P. Morgan & Co./Lehman Brothers/Pacific Growth

Equities Inc.

Company Counsel: Palmer & Dodge

Manager Counsel: Debevoise & Plimpton

Auditor: Pricewaterhouse Coopers LLP

The Company:

Develops chromatography equipment. The company’s patented and proprietary phage display technology (Phage Display) is a versatile, high throughput technology platform which the company believes can reduce costs, shorten development times and lead to the commercialization of more effective products in these fields. The company also develops, manufactures and sells fully-integrated chormatography separations systems under the Biotage trade name.

Venture Backers:

Healthcare Ventures LLC

Alta Partners

BancBoston Ventures

Loeb Partners Corp.

Chase Capital Partners

New York Life Venture Capital Group

Hambrecht & Quist

Prince Ventures

Charter Growth Capital

Granite Ventures LLC

Rho Management

Geneva MM Investors

Gateway Associates LP

Oak Investment Partners

Financing Rounds:

Number of Round Amt.

Round # Round Date Stage Investors ($ thousands)

1 08/01/1995 4 Early Stage 4000.0

2 10/01/1996 9 Expansion 13450.0

3 08/01/1998 10 Expansion 31354.2

Financials:

(Data in $ millions)

Y/E

12/31/99

Total Revenues: $16.8

Net Income: -13.2